546 related articles for article (PubMed ID: 30203227)
1. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
[TBL] [Abstract][Full Text] [Related]
2. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.
Prendergast GC; Malachowski WJ; Mondal A; Scherle P; Muller AJ
Int Rev Cell Mol Biol; 2018; 336():175-203. PubMed ID: 29413890
[TBL] [Abstract][Full Text] [Related]
3. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
Labadie BW; Bao R; Luke JJ
Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
[TBL] [Abstract][Full Text] [Related]
4. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
Fujiwara Y; Kato S; Nesline MK; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Treat Rev; 2022 Nov; 110():102461. PubMed ID: 36058143
[TBL] [Abstract][Full Text] [Related]
6. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
7. What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past.
Yao Y; Liang H; Fang X; Zhang S; Xing Z; Shi L; Kuang C; Seliger B; Yang Q
J Exp Clin Cancer Res; 2021 Feb; 40(1):60. PubMed ID: 33557876
[TBL] [Abstract][Full Text] [Related]
8. Current Challenges for IDO2 as Target in Cancer Immunotherapy.
Mondanelli G; Mandarano M; Belladonna ML; Suvieri C; Pelliccia C; Bellezza G; Sidoni A; Carvalho A; Grohmann U; Volpi C
Front Immunol; 2021; 12():679953. PubMed ID: 33968089
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated.
Charehjoo A; Majidpoor J; Mortezaee K
Int Immunopharmacol; 2023 May; 118():110032. PubMed ID: 36933494
[TBL] [Abstract][Full Text] [Related]
10. Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
Sumitomo M; Takahara K; Zennami K; Nagakawa T; Maeda Y; Shiogama K; Yamamoto Y; Muto Y; Nukaya T; Takenaka M; Fukaya K; Ichino M; Sasaki H; Saito K; Shiroki R
Cancer Sci; 2021 Mar; 112(3):1038-1047. PubMed ID: 33410234
[TBL] [Abstract][Full Text] [Related]
11. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
Zhai L; Spranger S; Binder DC; Gritsina G; Lauing KL; Giles FJ; Wainwright DA
Clin Cancer Res; 2015 Dec; 21(24):5427-33. PubMed ID: 26519060
[TBL] [Abstract][Full Text] [Related]
12. The ups, downs and new trends of IDO1 inhibitors.
Chen S; Tan J; Zhang A
Bioorg Chem; 2021 May; 110():104815. PubMed ID: 33773223
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors.
Schramme F; Crosignani S; Frederix K; Hoffmann D; Pilotte L; Stroobant V; Preillon J; Driessens G; Van den Eynde BJ
Cancer Immunol Res; 2020 Jan; 8(1):32-45. PubMed ID: 31806638
[TBL] [Abstract][Full Text] [Related]
15. 4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth.
Panda S; Pradhan N; Chatterjee S; Morla S; Saha A; Roy A; Kumar S; Bhattacharyya A; Manna D
Sci Rep; 2019 Dec; 9(1):18455. PubMed ID: 31804586
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
Front Immunol; 2021; 12():800630. PubMed ID: 35003126
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development.
Zhu MMT; Dancsok AR; Nielsen TO
Curr Oncol Rep; 2019 Jan; 21(1):2. PubMed ID: 30659394
[TBL] [Abstract][Full Text] [Related]
18. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
[TBL] [Abstract][Full Text] [Related]
19. Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers.
Komiya T; Huang CH
Front Oncol; 2018; 8():423. PubMed ID: 30338242
[TBL] [Abstract][Full Text] [Related]
20. Targeting tryptophan availability to tumors: the answer to immune escape?
Badawy AA
Immunol Cell Biol; 2018 Nov; 96(10):1026-1034. PubMed ID: 29888434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
